Sugi Predict

Sugi Predict / Compounds / SCHEMBL1605255

SCHEMBL1605255

SCHEMBL1605255

Brc1occ2ccccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.39
▸ CYP2A6 P11509 6/20 0.39
▸ HSD17B10 Q99714 5/20 0.39
▸ TSHR P16473 3/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ CYP1A2 P05177 5/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ POLB P06746 3/20 0.37
▸ HPRT1 P00492 1/20 0.36
▸ HPGD P15428 2/20 0.33
▸ ALOX12 P18054 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ CYP1B1 Q16678 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ PARP1 P09874 2/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ KEAP1 Q14145 1/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propionaldehyde SCHEMBL28849694 0.83 PTPN1 (0.33) ALDH1A1TDP1CYP1A2CYP2C9CYP2C19
SCHEMBL28849693 0.82 ALDH1A1 (0.36) ALDH1A1TDP1CYP1A2CYP2C19HPGD
SCHEMBL31267442 0.71 CYP2A6 (0.39) ALDH1A1CYP2A6HSD17B10TDP1CYP1A2
SCHEMBL21333447 0.71 CYP2A6 (0.39) ALDH1A1CYP2A6MEN1KMT2APTPN1
SCHEMBL1097671 0.70 CYP2A6 (0.42) ALDH1A1CYP2A6HSD17B10TSHRTDP1
SCHEMBL4079696 0.70 CYP2A6 (0.42) ALDH1A1CYP2A6HSD17B10TSHRTDP1
SCHEMBL276956 0.70 ALDH1A1 (0.39) ALDH1A1CYP2A6HSD17B10TSHRTDP1
SCHEMBL21179481 0.70 ALDH1A1 (0.39) ALDH1A1CYP2A6HSD17B10TSHRTDP1
SCHEMBL4897405 0.70 ALDH1A1 (0.39) ALDH1A1CYP2A6HSD17B10TSHRTDP1
SCHEMBL2012336 0.70 ALDH1A1 (0.39) ALDH1A1CYP2A6HSD17B10TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724440-A1 METHODS OF TREATING INFLAMMATORY DISEASES Interline Therapeutics, Inc. (US) 2026-04-15 — — EP disclosed
WO-2024254539-A1 METHODS OF TREATING INFLAMMATORY DISEASES INTERLINE THERAPEUTICS, INC. (US) 2024-12-12 — — WO disclosed
CN-109422778-A Organo-metallic compound and organic luminescent device and diagnosis composition including it 三星电子株式会社 2019-03-05 — — CN disclosed
CN-104540826-B Spiro-fused piperidine derivatives useful as inhibitors of extrarenal potassium channels 默沙东公司 2018-04-20 — — CN disclosed
CN-105153013-B The synthetic method of the ketone of 6 bromine isoindoline 1 苏州昊帆生物科技有限公司 2017-12-29 — — CN disclosed
CN-104245685-B The production method of (acetylene-1,2-diyl) double (isobenzofuran-1,3-diketone) 聂克斯姆化学有限公司 2016-09-07 — — CN disclosed
CN-103459382-B For suppressing the heterocyclic compound of PASK 拜奥埃内杰尼克斯公司 2016-06-29 — — CN disclosed
US-9221835-B2 Spirocyclic derivatives as antiparasitic agents ZOETIS SERVICES LLC (US) 2015-12-29 — — US disclosed
US-20150210710-A1 SPIROCYCLIC DERIVATIVES AS ANTIPARASITIC AGENTS ZOETIS SERVICES LLC 2015-07-30 — — US disclosed
EP-2892902-A1 SPIROCYCLIC DERIVATIVES AS ANTIPARASITIC AGENTS Zoetis LLC (US) 2015-07-15 — — EP disclosed
CN-101189243-A Substituted heterocycles and their use as CHK1, PDK1 and PAK inhibitors ASTRAZENECA AB (SE) 2008-05-28 — — CN disclosed
US-20080045503-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2008-02-21 — — US disclosed
US-20070281938-A1 Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 AMGEN INC. 2007-12-06 — — US disclosed
US-20070197598-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2007-08-23 — — US disclosed
US-7253196-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 AMGEN, INC. (US) 2007-08-07 — — US disclosed
WO-2007061661-A2 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AMGEN INC. (US) 2007-05-31 — — WO disclosed
CN-1964956-A Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN (US) 2007-05-16 — — CN disclosed
EP-1753736-A2 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 Amgen Inc. (US) 2007-02-21 — — EP disclosed
US-20060142357-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2006-06-29 — — US disclosed
WO-2005116002-A2 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AMGEN INC. (US) 2005-12-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045503-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD3B1, HSD17B1 ALDH1A1 100/4885CYP2A6 170/4885HSD17B10 20/4885
US-20070197598-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 71/4885CYP2A6 240/4885HSD17B10 17/4885
US-20150210710-A1 SPIROCYCLIC DERIVATIVES AS ANTIPARASITIC AGENTS AVPR1A, AVPR1B, AVPR2 ALDH1A1 368/4885CYP2A6 167/4885HSD17B10 1568/4885
US-20060142357-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD3B1, HSD17B1 ALDH1A1 100/4885CYP2A6 170/4885HSD17B10 20/4885
US-20070281938-A1 Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 HSD11B1, HSD3B1, HSD17B1 ALDH1A1 76/4885CYP2A6 159/4885HSD17B10 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.